Spero Therapeutics (SPRO) Interest & Investment Income (2017 - 2026)
Spero Therapeutics posted quarterly Interest & Investment Income of $336000.0 for Q1 2026, down 61.11% year-on-year from $864000.0 in Q1 2025, and down 10.64% on a QoQ basis from $376000.0 in Q4 2025.
Spero Therapeutics (SPRO) has 10 years of Interest & Investment Income data on file, last reported at $336000.0 in Q1 2026.
- For the quarter ending Q1 2026, Interest & Investment Income fell 61.11% year-over-year to $336000.0; the trailing twelve-month figure through Mar 2026 stood at $2.0 million (down 53.56% YoY), and the FY2025 full-year result was $2.5 million, down 46.95% from the prior year.
- Interest & Investment Income for Q1 2026 stood at $336000.0, down from $376000.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $1.3 million in Q1 2024 and bottomed at $72000.0 in Q1 2022.
- The 5-year median for Interest & Investment Income is $864000.0 (2025), against an average of $742764.7.
- The widest annual swing landed in 2023, when Interest & Investment Income jumped 1237.5%; it then plunged 63.42% in 2025.
- A 5-year view of Interest & Investment Income shows it stood at $715000.0 in 2022, then surged by 45.87% to $1.0 million in 2023, then declined by 1.44% to $1.0 million in 2024, then slumped by 63.42% to $376000.0 in 2025, then declined by 10.64% to $336000.0 in 2026.
- The last three Interest & Investment Income figures came in at $336000.0 (Q1 2026), $376000.0 (Q4 2025), and $532000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 7.90 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 114.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 305,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 26.60 Mn |
| 10 | Spero Therapeutics | 162.39 Mn | 106.26 Mn | - | 336,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 336,000.00 |
| Dec 31, 2025 | 376,000.00 |
| Sep 30, 2025 | 532,000.00 |
| Jun 30, 2025 | 740,000.00 |
| Mar 31, 2025 | 864,000.00 |
| Dec 31, 2024 | 1.03 Mn |
| Sep 30, 2024 | 1.18 Mn |
| Jun 30, 2024 | 1.20 Mn |
| Mar 31, 2024 | 1.33 Mn |
| Dec 31, 2023 | 1.04 Mn |
| Sep 30, 2023 | 950,000.00 |
| Jun 30, 2023 | 982,000.00 |
| Mar 31, 2023 | 963,000.00 |
| Dec 31, 2022 | 715,000.00 |
| Sep 30, 2022 | 208,000.00 |
| Jun 30, 2022 | 111,000.00 |
| Mar 31, 2022 | 72,000.00 |
| Dec 31, 2021 | 76,000.00 |
| Sep 30, 2021 | 90,000.00 |
| Jun 30, 2021 | 82,000.00 |
| Mar 31, 2021 | 98,000.00 |
| Dec 31, 2020 | 49,000.00 |
| Sep 30, 2020 | 29,000.00 |
| Jun 30, 2020 | 86,000.00 |
| Mar 31, 2020 | 237,000.00 |
| Dec 31, 2019 | 320,000.00 |
| Sep 30, 2019 | 403,000.00 |
| Jun 30, 2019 | 367,000.00 |
| Mar 31, 2019 | 239,000.00 |
| Dec 31, 2018 | 442,000.00 |
| Sep 30, 2018 | 472,000.00 |
| Jun 30, 2018 | 15,000.00 |
| Mar 31, 2018 | 172,000.00 |
| Dec 31, 2017 | 138,000.00 |
| Sep 30, 2017 | 124,000.00 |
| Jun 30, 2017 | 52,000.00 |
| Mar 31, 2017 | -11,000.00 |